AutekBio, Inc is a biopharmaceutical contract development and manufacturing company (CDMO) focusing on producing therapeutic proteins and antibodies from mammalian cell culture. The company offers a comprehensive "from DNA to NDA" solution for biopharmaceutical firms through its proprietary technology platforms. Established in 2006, the company is headquartered in the US, with a manufacturing facility in the Free Trade Zone of Beijing. AutekBio's Series B funding round on 22 October 2007 secured $1.00M from Acorn Campus Ventures.
AutekBio's mission revolves around being a premier China-based biologic CMO for the global market, focusing solely on service and CMO without internal product development or drug discovery programs. The company aims to be a gateway to the Chinese market while opening new frontiers in manufacturing quality therapeutic biologics and delivering affordable biologics to those in need.
With a specific emphasis on biotechnology, AutekBio positions itself as a trusted partner for pharmaceutical companies seeking quality therapeutic biologics, leveraging its unique expertise in mammalian cell culture-based production. The company's strategic location in the Free Trade Zone of Beijing provides it with a convenient base from which to serve the needs of its global partners.
Overall, AutekBio, Inc's alignment with the rapidly growing biopharmaceutical industry and its focus on leveraging Chinese market opportunities make it an intriguing prospect for potential investors seeking exposure to this niche.| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $1.00M | 1 | Acorn Campus Ventures | 22 Oct 2007 |
| Series A | $1.10M | 1 | Acorn Campus Ventures | 07 Aug 2007 |
No recent news or press coverage available for AutekBio, Inc.
We care about your data, and we'd love to use cookies make your experience better.
